1. Home
  2. MREO vs ASA Comparison

MREO vs ASA Comparison

Compare MREO & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • ASA
  • Stock Information
  • Founded
  • MREO 2015
  • ASA 1958
  • Country
  • MREO United Kingdom
  • ASA United States
  • Employees
  • MREO N/A
  • ASA N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • ASA Precious Metals
  • Sector
  • MREO Health Care
  • ASA Industrials
  • Exchange
  • MREO Nasdaq
  • ASA Nasdaq
  • Market Cap
  • MREO 406.5M
  • ASA 415.9M
  • IPO Year
  • MREO N/A
  • ASA N/A
  • Fundamental
  • Price
  • MREO $2.57
  • ASA $28.38
  • Analyst Decision
  • MREO Strong Buy
  • ASA
  • Analyst Count
  • MREO 6
  • ASA 0
  • Target Price
  • MREO $7.83
  • ASA N/A
  • AVG Volume (30 Days)
  • MREO 1.4M
  • ASA 44.1K
  • Earning Date
  • MREO 05-14-2025
  • ASA 04-01-2025
  • Dividend Yield
  • MREO N/A
  • ASA 0.14%
  • EPS Growth
  • MREO N/A
  • ASA 1102.63
  • EPS
  • MREO N/A
  • ASA 6.06
  • Revenue
  • MREO $1,000,000.00
  • ASA $2,140,037.00
  • Revenue This Year
  • MREO N/A
  • ASA N/A
  • Revenue Next Year
  • MREO N/A
  • ASA N/A
  • P/E Ratio
  • MREO N/A
  • ASA $4.68
  • Revenue Growth
  • MREO N/A
  • ASA N/A
  • 52 Week Low
  • MREO $2.25
  • ASA $14.55
  • 52 Week High
  • MREO $5.02
  • ASA $28.90
  • Technical
  • Relative Strength Index (RSI)
  • MREO 45.10
  • ASA 71.39
  • Support Level
  • MREO $2.49
  • ASA $24.57
  • Resistance Level
  • MREO $2.66
  • ASA $28.90
  • Average True Range (ATR)
  • MREO 0.14
  • ASA 0.85
  • MACD
  • MREO 0.03
  • ASA 0.27
  • Stochastic Oscillator
  • MREO 80.49
  • ASA 88.42

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

Share on Social Networks: